|1.||Castellani, Patrizia: 1 article (03/2013)|
|2.||Truini, Mauro: 1 article (03/2013)|
|3.||Balza, Enrica: 1 article (03/2013)|
|4.||Rubartelli, Anna: 1 article (03/2013)|
|5.||Delfino, Laura: 1 article (03/2013)|
|6.||Coqueret, Olivier: 1 article (11/2010)|
|7.||Faure, Sébastien: 1 article (11/2010)|
|8.||Guihot, Anne-Laure: 1 article (11/2010)|
|9.||Corre, Isabelle: 1 article (11/2010)|
|10.||Hein, Lutz: 1 article (11/2010)|
03/01/2013 - "The chemopreventive treatments gave unsatisfactory results because administration of IB one day after the 3-MCA injection only slightly delayed the tumor development, whereas SASP dispensed under the same conditions resulted in accelerated tumorigenesis. "
11/15/2010 - "In vitro, inactivation or invalidation of AT2R inhibited proliferation of LL/2 and 3-MCA tumor cells, respectively. "
11/15/2010 - "Tumor induction by 3-MCA was significantly delayed in AT2R-KO compared to wild-type mice (56 days vs. 28 days). "
11/15/2010 - "Proliferation index of LL/2 and 3-MCA tumor cells was evaluated by expression of Ki-67. "
04/01/1982 - "Clones from tumors induced with 10 mg of 3-MCA were found to be less tumorigenic than clones from tumors induced with 5 mg of 3-MCA. "
|2.||Sarcoma (Soft Tissue Sarcoma)
02/20/1991 - "Altogether 16 sarcomas were immunogenic, with the highest frequency of TSTA+ tumors (10/11 and 5/6) in the groups given 1.0 and 0.1 mg of 3-MCA respectively, the lowest (1/5) in that with 0.01 mg of carcinogen; ras mutations occurred in the DNAs of 11 out of the 16 TSTA+ sarcomas, but none of the DNAs of the 6 TSTA- tumors showed ras mutation. "
|4.||Foreign Bodies (Foreign Body)
|1.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|4.||tumor-associated transplantation antigen (TSTA)